Home DailyMed 977b6998-2bd0-4c50-bfb6-d64e2e8d54f1 National Council for Prescription Drug Programs indexing - billing unit Drug label information. FDA.report displays public Structured Product Labeling data from DailyMed and legacy FDA.report DailyMed cache rows. This page is not medical advice, prescribing advice, or a substitute for the official label reviewed by a qualified healthcare professional. Labeling can change; when a current hydrated DailyMed SPL record is available, FDA.report shows that newer record before legacy cached files.
Manufacturer National Council for Prescription Drug Programs
Effective date 2012-07-24
Label type Indexing - Billing Unit
Version 1
Source full-release
Hydrated at 2026-06-05 02:17:39 Orange Book application contexts# All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
Orange Book application contexts page 1 of 1 · 1 matching rows.
Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N022023-001 EMEND FOSAPREPITANT DIMEGLUMINE EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 N022023-002 EMEND FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 1 matching rows.
Application-product, TE code table Application-product TE code N022023-002 AP
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 3 · 86 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 84e616aacf4f…2026-09-14 22:38:34 2026-08 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 84e616aacf4f…2026-08-18 06:07:40 2026-07 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** POWDER / INTRAVENOUS RLD 2008-01-25 5c6f7cd8ea54…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N022023-001 EMEND EQ 115MG BASE/VIAL POWDER / INTRAVENOUS RLD 2008-01-25 5d02ea3f76ae…2022-04-08 23:34 UTC 2022-04 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N022023-001 EMEND EQ 115MG BASE/VIAL POWDER / INTRAVENOUS RLD 2008-01-25 4b0b4de00fa7…2022-04-04 05:41 UTC 2022-04 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N022023-001 EMEND EQ 115MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** POWDER / INTRAVENOUS RLD 2008-01-25 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022023-002 EMEND EQ 150MG BASE/VIAL POWDER / INTRAVENOUS AP RLD, RS 2010-11-12 74a2ff9319b5…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 2 · 43 observed states.
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2019-12-13 00:20 UTC 2019-12 N022023-001 5691336 2019-03-04 Drug substance, Drug product 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022023-001 5691336*PED 2019-09-04 Pediatric extension 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022023-002 5691336 2019-03-04 U-2265 Drug substance, Drug product 74a2ff9319b5…2019-12-13 00:20 UTC 2019-12 N022023-002 5691336*PED 2019-09-04 Pediatric extension 74a2ff9319b5…2019-12-14 00:12 UTC 2019-12 N022023-001 5691336 2019-03-04 Drug substance, Drug product 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022023-001 5691336*PED 2019-09-04 Pediatric extension 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022023-002 5691336 2019-03-04 U-2265 Drug substance, Drug product 3f01610625f2…2019-12-14 00:12 UTC 2019-12 N022023-002 5691336*PED 2019-09-04 Pediatric extension 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N022023-001 5691336 2019-03-04 Drug substance, Drug product b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022023-001 5691336*PED 2019-09-04 Pediatric extension b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022023-002 5691336 2019-03-04 U-2265 Drug substance, Drug product b00525d2431f…2019-09-15 20:21 UTC 2019-09 N022023-002 5691336*PED 2019-09-04 Pediatric extension b00525d2431f…2019-07-19 19:46 UTC 2019-07 N022023-001 5691336 2019-03-04 Drug substance, Drug product ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022023-001 5691336*PED 2019-09-04 Pediatric extension ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022023-002 5691336 2019-03-04 U-2265 Drug substance, Drug product ea99ee380514…2019-07-19 19:46 UTC 2019-07 N022023-002 5691336*PED 2019-09-04 Pediatric extension ea99ee380514…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 3 · 92 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.